Adefovir
๐ Adefovir dipivoxil should not normally be given before the person has had lamivudine treatment.
It may be given on its own or with lamivudine when:
- Hepatitis B virus has become resistant to lamivudine, OR
- The virus is likely to become resistant to lamivudine quickly, with risk of serious liver disease.
๐ About
Always check the BNF link here for up-to-date prescribing information.
- Nucleotide analogue used in the treatment of chronic Hepatitis B infection.
- Structurally related to the purine base adenine.
โ๏ธ Mode of Action
- Converted intracellularly to the diphosphate form.
- Acts by inhibiting hepatitis B virus DNA synthesis via competition for reverse transcriptase and incorporation into viral DNA.
- Not well absorbed orally, so given as the prodrug adefovir dipivoxil.
๐ฏ Indications
- Chronic Hepatitis B (in patients with lamivudine resistance, relapse, or intolerance to interferon-based therapies).
๐ Dose
- Chronic Hepatitis B: 10 mg once daily (PO), in patients with normal renal function.
๐ Guidance (NICE)
- For adults with chronic hepatitis B where:
- Interferon/peginterferon treatment has not worked, or relapse occurred.
- Patient cannot tolerate interferon-based therapy.
- Severe side effects developed from prior treatment.
๐ Interactions
- No significant interactions reported.
โ ๏ธ Cautions
- Adjust dose in renal impairment.
- Nephrotoxicity may occur.
๐ซ Contraindications
๐ค Side Effects
- GI upset: nausea, flatulence, diarrhoea, dyspepsia.
- Rash, headache, hypophosphataemia.
- Serious: lactic acidosis, hepatitis, renal failure.
- Severe hepatomegaly with steatosis (rare).
๐ References